Tag: Myositis
Anti-OJ autoantibodies are myositis-specific autoantibodies (MSAs) that can be found in < 5% of patients with idiopathic inflammatory myopathies (IIMs). They presumably target isoleucyl-tRNA synthetase and, as such, are part of the group of the anti-aminoacyl-tRNA synthetases, of which anti-Jo-1 is the most prevalent.
09.01.2020
 
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune diseases (collectively referred to as myositis), which mainly include the subtypes of polymyositis, dermatomyositis, immune-mediated necrotizing myopathy (IMNM) and sporadic inclusion body myositis (sIBM).
07.10.2019
 
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune diseases (collectively referred to as myositis), which mainly include the subtypes of polymyositis, dermatomyositis, immune-mediated necrotizing myopathy (IMNM) and sporadic inclusion body myositis (sIBM).
23.08.2019
 
Objective: Interstitial lung disease (ILD) is the most severe complication of idiopathic inflammatory myositis (IIM), resulting in significant increase in morbidity and mortality and for which the best treatment remains controversial. We conducted a meta-analysis to evaluate the efficacy of therapies used for the management of IIM-related ILD
17.04.2019
 
Myositis as an adverse event of immune checkpoint blockade for cancer therapy; Myositis as a complication of immune checkpoint blockade
01.07.2018
 
Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis
07.03.2018
 
As autoantibodies play a role in the newly proposed classifications, it is expected that measurement of myositis-specific autoantibodies will be increasingly introduced in clinical practice.
13.02.2018